Status:

ACTIVE_NOT_RECRUITING

Feasibility of the Maastro Applicator in Rectal Cancer

Lead Sponsor:

Maastricht Radiation Oncology

Collaborating Sponsors:

Varian Medical Systems

Conditions:

Rectal Cancer

Feasibility

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The goal of this interventional pilot trial is to confirm that Maastro endoluminal HDR ( High Dose Radiation) contact brachytherapy boosting is feasible and may increase the chance of functional organ...

Detailed Description

The goal of this clinical trial is to confirm that Maastro endoluminal HDR contact brachytherapy boosting is feasible and may increase the chance of functional organ sparing of the rectum in patients ...

Eligibility Criteria

Inclusion

  • ≥ 18 years of age and capable of giving informed consent.
  • Adenocarcinoma of the rectum classified cT (clinical Tumor) 2-3b, \< 5 cm largest diameter and \< ½ circumference (MRI staging), N0-N1 (any node \< 8 mm diameter), M0
  • Operable patient
  • Tumor accessible to the Maastro applicator with a distance from the lower tumor border to the anal verge ≤10 cm
  • No comorbidity preventing treatment
  • Adequate birth control for women of child-bearing potential
  • Follow-up possible.

Exclusion

  • Tumor extending into the anal canal.
  • Stop of anti-coagulants (except ≤100 mg aspirin/day) is medically contraindicated.
  • Presence of coagulation disorder resulting in an increased bleeding risk.
  • Prior pelvic radiation therapy (excluding the abovementioned neoadjuvant treatment).
  • Prior surgery or chemotherapy for rectal cancer (excluding the abovementioned neoadjuvant treatment).
  • Inflammatory bowel disease (IBD).
  • (Systemic) treatment possibly causing rectal or genitourinary toxicity for a separate active malignancy.
  • World Health Organization performance status (WHO-PS) ≥ 3.
  • Life expectancy of \< 6 months.
  • Pregnant women.

Key Trial Info

Start Date :

August 27 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2031

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT06087718

Start Date

August 27 2024

End Date

April 1 2031

Last Update

August 14 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Maastro

Maastricht, Limburg, Netherlands, 6229ET